32 results about "Blocking drug" patented technology

The use of an intravascular cooling element to induce hypothermia in connection with a medical procedure. According to a first aspect of the present, invention, a coronary bypass procedure is conducted in which a patient's blood is oxygenated with the patient's lungs and in which blood is circulated using the patient's heart or using an intracorporeal pump. The procedure preferably comprises: (a) positioning a heat transfer element in a blood vessel of a patient; (b) cooling the body of the patient to less than 35° C., more preferably 32±2° C., using the heat transfer element; and (c) forming a fluid communicating graft between an arterial blood supply and the coronary artery. The body of the patient is preferably heated to about 37° C. using the heat transfer element subsequent to the step of forming the fluid communicating graft. According to a further aspect of the invention, a hypothermic medical procedure is provided while a patient is in a conscious or semiconscious state, comprising (a) administering a beta-blocking drug to the patient; (b) delivering a heat transfer element to a blood vessel of the patient; and (c) cooling a region of the patient or the body of the patient to less than 35° C. using the heat transfer element.

A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or another agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or its other agonist in an amount sufficient to at least partially block the pharmacologic defects of the drug or its other agonist while there is a substantial amount of the drug or other agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or other agonist. In another embodiment, the drug or its other agonist is first administered and the antagonist is self-administered by a subject in a manner which mimics the use of the drug thereby counter-conditioning the drug user to the stimuli associated with the normal administration of the drug. The invention further provides a method of therapeutically treating psychophysiologic diseases and disorders involving neuronal dysregulation. The method additionally provides a pharmacologic composition for the treatment and reduction of drug dependence and which relies upon a combination of an agonist and antagonist.

The invention discloses an application of an N-acetanilide cationic compound in preparation of a local nerve blocking drug. The cationic compound is a quaternary ammonium salt compound and has a structure as shown in a formula (I), wherein X is a halogen atom. When used alone, the compound has the characteristics of good safety performance, strong nerve blocking effect and the like, can take a reversible and durable local anaesthesia effect in vivo and can be used as a local anaesthesia drug or an analgesic drug which is long-acting and / or capable of realizing selective blocking. Particularly, a composition composed of the compound and other local anaesthesia drugs has the remarkable characteristics of high effect taking speed, strong effect, long acting time, little nerve injury and the like when used for nerve blocking.

Cholesterol-uptake-blocking drugs inhibit angiogenesis and are useful to inhibit diseases perpetuated by angiogenesis. Cholesterol reduction with the use of the drugs increases the intratumoral level of thrombospondin-1, an angiogenesis inhibitor. Ezetimibe (Zetia®), a specific cholesterol-uptake blocking drug, also retards the growth of human tumors, most preferably in combination with low-cholesterol diet. The pharmacologic reduction in serum cholesterol retards prostate cancer growth by inhibiting tumor angiogenesis to combat the growth of prostatic tumors which are directly accelerated by hypercholesterolemia.

The invention discloses an automatic quantitative grabbing device of traditional Chinese medicine decoction pieces. The automatic quantitative grabbing device of traditional Chinese medicine decoctionpieces comprises a medicine blocking brush (1), a split feeding roller (2), a master control board (3), an open bucket motor (4), a feeding motor (5), a movable door lifting lever (6), a hopper uppercover (7), a scale bottom support (8), a buffer device (9), a sensor buffer pad (10), a roller supporting frame (11), a weighing sensor assembly (12), a traditional Chinese medicine decoction piece hopper (13), medicine lifting teeth (21), a medicine storage groove (22) and a positioning pin (23). The computer program control technology and the mechanical structure technology are adopted, scientific, rapid and accurate grabbing of the traditional Chinese medicine decoction pieces can be achieved, the problems that according to an existing medicine grabbing mechanism, a medicine feeding rolleris poor in fine adjusting capacity, a weighing sensor is affected easily by adjusting vibration, and the integration of a control system is poor are solved, and the beneficial effects of being accurate in medicine taking amount, free of external effect on weighing, small in medicine falling vibration, low in noise, high in efficiency and the like are achieved.

The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device can achieve both optical and medical functions. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject, wherein the drug partitions between the reservoir domain and the barrier layer, and the equilibrium drug solubility in the reservoir domain is at least five folds higher than that in the barrier layer.

The invention relates to the technical field of automatic drug selling, in particular to an automatic drug selling pharmacy precise in drug feeding. The drug selling pharmacy comprises a rack, a plurality of combined chambers for storing drugs are fixed to the rack, each combined chamber comprises a plurality of oblique chamber bodies, blocking pieces for blocking drug boxes are arranged at the bottoms of the chamber bodies, and a drug feeding and conveying machine is arranged outside the rear portion of the rack; a drug feeding module is arranged in the rear portion of the rack, and a drug feeding mechanism is slidably arranged on the drug feeding module, conveys the drug boxes from the drug feeding and conveying machine to the chamber bodies and comprises a U-shaped groove plate and a first slideway located above the U-shaped groove plate; an included angle between the bottom edge of the cross section of the first slideway and the horizontal direction is greater than 0 degree, a first side plate and a second side plate are disposed on the two sides of the first slideway respectively and both are perpendicular to the bottom face of the first slideway, the first side plate is lowerthan the second side plate, and a first side edge of the upper end of the first side plate and a second side edge of one side of the bottom of the corresponding chamber body are parallel to each other and aligned in the vertical direction. The drug selling pharmacy is accurate in drug feeding.

Disclosed are a prescription of intravenous medication for blocking a heroin or morphine intoxication path and its using. The prescription of intravenous infusion includes Cerebrolysin, Piracetam, Cimetidine, Scopolamine Butylbromide, Nefopam, B.C Complex, Vitamin B1, Ascorbic Acid, Ketorolac, Guronsan, Hyoscine Butylbromide and Sukerin. The prescription activates a patient's liver and circulatory system to block drug intoxication. The using for blocking drugs includes an acute withdrawal part, wherein the prescription of intravenous infusion is injected and the timing of drug administration and the safe dosage are controlled according to clinical symptoms, and an appropriate amount of a supplementary medicine such as Haloperidol is added, and the processes of detoxication, relieving symptoms, suppressing restlessness, and sobering are conducted to block acute withdrawal symptoms of an acute withdrawal addict quickly and successfully.

The invention relates to an insect-repelling cable, which includes a wire core, an insulating layer and a protective layer; a repelling layer is wrapped outside the protective layer, and the repelling layer is installed equidistantly in the axial direction in the repelling layer There are drug rings, and drug spraying chambers made of elastic materials are equidistantly arranged in the circumferential direction of each drug ring, and insect repellants are filled in each of the drug spraying chambers; A closed helical coil is also installed on the symmetrical inner wall of the group, and the axis of the helical coil is not parallel to the axis of the drug ring; anti-clogging nozzles are provided on each of the spray chambers, and each of the anti-clogging nozzles is arranged along the drug ring. The radial direction extends outward and extends to the outer peripheral wall of the repelling layer; the cable has a simple structure and does not require frequent maintenance, which can effectively drive away insects and ants around the cable and effectively prolong the service life of the cable.

The invention relates to a calcium channel blocking drug molecule co-crystal and a preparation method thereof. The general molecular formula of the calcium channel blocking drug molecule co-crystal is(C20H25ClN2O5).(X).((CH3)2CHOH)n, wherein X represents one of benzene sulfonic acid, maleic acid and fumaric acid; and n represents the number of isopropanol molecules, and n is greater than 0 and less than and equal to 1. A co-crystal drug provided solves the solubility and stability problems of existing levamlodipine, and is beneficial to the improvement of the stability of levamlodipine tablets, preparation of the co-crystal is simple, the cost is low, the crystal form of the prepared crystal is regular, the particle size is uniform, and industrial production prospects are achieved.

The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.

The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.

The invention relates to a method for inducing a rapid eye movement sleep behavior disorder (RBD) phenotype capable of transforming to a Parkinson phenotype in a non-human subject animal. The method comprises the following steps: 1) stereotactically injecting a substance capable of inducing a pathological change of synuclein into a unilateral or bilateral mesocephalon sublaterodorsal tegmental nucleus (SLD) of a non-human subject animal; 2) evaluating the induction of the RBD phenotype of the non-human tested animal; and 3) evaluating the induction of the Parkinson phenotype in the RBD animal. The invention also relates to a preparation method of a synuclein pathological RBD model. Prefabricated fibrous bodies (PFFs) capable of inducing synuclein pathology is stereodirectionally injected into an SLD nucleus, a mouse RBD model capable of transforming to a Parkinson phenotype is constructed by virtue of a pathology induction characteristic of "dissemination-nucleation" of the fibrous bodies, and the model is expected to provide an important animal model basis for clarification of pathogenesis and Parkinson's disease transforming of RBD and research and development of effective blocking drugs in a future research.

The invention discloses a catheter for clinical intravascular interventional treatment. The catheter for clinical intravascular interventional treatment comprises a filling pipe. A filling pipe limiting structure is arranged in the middle of the filling pipe. A connection catheter seat is arranged on the outer surface of one end of the filling pipe. The outer surface of one end of the connection catheter seat is fixedly connected with a second connection catheter opening, a protection and antifouling structure is arranged on the outer surface of one end of the second connection catheter opening, a connection outer-pipe is arranged on the outer surface of the other end of the filling pipe, an inflatable bone tamp is arranged on the outer surface of one end of the connection outer-pipe, anda catheter body is arranged on the outer surface of the front end of the inflatable bone tamp. According to the catheter for clinical intravascular interventional treatment, the filling pipe limitingstructure is arranged so that the position of the filling pipe can be limited, and the work of medical staff is prevented from being obstructed; an anti-blocking drug injection device is arranged so that the impact of an injected drug on blood vessels can be avoided, and a patient is prevented from feeling uncomfortable; and the protection and antifouling structure is arranged, the sanitation of an end opening of the catheter is conveniently ensured, and the next use is facilitated.

A method for the fail-safe termination of in vivo drug delivery from an implantable drug delivery system, the method comprising: providing an implantable drug delivery system comprising: a housing having a reservoir for containing a drug, and a port for dispensing the drug to a patient; and an emergency deactivation unit disposed between the reservoir and the port, the emergency deactivation unit comprising a composite structure comprising a biocompatible ferromagnetic mesh open to fluid flow and a hydrophobic meltable material, the hydrophobic meltable material comprising at least one hole therein for enabling a fluid to pass through the hydrophobic meltable material; implanting the implantable drug delivery system within a patient; enabling the drug to flow from the reservoir, through the at least one hole in the hydrophobic meltable material and out the port; and when drug flow is to be terminated, applying a magnetic field to the composite structure, such that a current is induced in the ferromagnetic mesh which heats the ferromagnetic mesh and melts the hydrophobic meltable material, thereby closing the at least one hole in the hydrophobic meltable material and blocking drug delivery to the patient.

The invention relates to an H2 receptor blocking drug efficacy related gene SLC22A1 polymorphism detection kit, comprising a test tube separately provided with each C1022T detection primer and each internal control gene detection primer, wherein the C1022T detection primer comprises the following sequence components: C1022T detection primer 1: 5'-GCAGACCTGT TCCGCACGTC-3'; C1022T detection primer 2: 5'-CAGACCTGTT CCGCACGAT-3'; C1022T detection primer 3: 5'-CACTCACAAC TATATTACA-3'; the internal control gene detection primer comprises the following sequence components: internal control primer 1:5'-AGCAAGCAGG AGTATGACG-3'; internal control primer 2: 5'-GAAAGGGTGT AACGCAACT-3'. Compared with the prior art, the kit has the advantages of high sensitivity, high specificity and short time consumption when the SLC22A1 gene mutation of samples such as fresh blood is detected.

The invention belongs to the technical field of a medicine, relates to a pharmaceutical composition for preventing or treating cold injury and thrombus, and particularly relates to use of a pharmaceutical composition including an M cholinoceptor blocking drug and an alpha1 receptor antagonist drug, and use of the pharmaceutical composition for preparing a drug for preventing or treating the cold injury, chimatlon, thrombus or protecting vascular endothelial cells. The invention is confirmed that the cold injury can be effectively prevented or treated by combination of the M cholinoceptor blocking drug and the alpha1 receptor antagonist drug; the thrombus can be effectively reduced; the thrombus forming length is shortened; the pharmaceutical composition has the function of protecting the vascular endothelial cells; the effect is much superior to that of a single drug; and the two drugs have synergistic effects by combination.

The invention belongs to the technical field of medicine carrying platforms, and particularly relates to a multifunctional composite stent and a preparation method and application thereof. Wherein the multifunctional composite stent has the characteristic of programmed release of therapeutic drugs, the tumor vascular blocking drugs loaded on the stents on the two sides can preferentially and rapidly release and damage tumor tissue vascular endothelial cells so as to cause necrosis of part of cancer cells in the tumor, and then the intermediate electrostatic spinning membrane releases chemotherapeutic drugs permanently, so that the tumor tissue vascular endothelial cells are damaged. The degradable electrostatic spinning membrane loaded with the chemotherapy drug can act on residual tumor cells for a long time, effectively kills the residual tumor cells and reduces the tumor recurrence rate, and the biocompatible stent loaded with the tumor blood vessel blocking drug is overlaid on the two sides of the degradable electrostatic spinning membrane loaded with the chemotherapy drug to form a sandwich structure; the technical problems that residual tumor cells are difficult to effectively kill and the tumor recurrence rate is high in the prior art are solved.

The invention relates to the technical field of medicine. Jellyfish stings are the most common marine injury worldwide, and acute circulatory failure caused by cardiovascular toxic components in jellyfish toxins is considered to be the main cause of death from jellyfish stings. The present invention also provides the application of different types of adrenergic receptor blocking drugs in the preparation of jellyfish toxin cardiotoxic antagonist drugs, and the different types of adrenergic receptor blocking drugs refer to α receptor blocking drugs, β receptor blocking drugs And α, β receptor blockers, especially non-selective α receptor blockers, non-selective β receptor blockers, selective long-acting β1 receptor blockers, selective short-acting β1 receptor blockers body blockers. The present invention finds that different types of adrenergic receptor blocking drugs can effectively antagonize the cardiotoxicity of jellyfish toxins at the three levels of cultured suckling rat cardiomyocytes, isolated hearts and whole animals, and can be developed as a preventive or therapeutic drug for jellyfish stings .

The invention provides a special-shaped drug feeding station, which includes a station frame assembly, a drug feeding channel assembly, a conveyor belt, a drug feeding transmission mechanism, a counting assembly, and a drug blocking plate assembly; at least one layer of drug feeding channel components is installed on the station On the frame assembly, each drug feeding channel assembly includes a plurality of drug feeding channels arranged side by side; each drug feeding channel is a hollow tubular member; a conveyor belt is installed at the bottom of each drug feeding channel, and the conveyor belt is driven by the drug feeding transmission mechanism. , which can transport the medicines put into the medicine feeding channel from the front end to the back end; the counting assembly is set in the medicine feeding channel for counting the medicines put into the medicine feeding channel; the medicine blocking plate assembly is installed behind the station frame assembly end, blocking the exit at the rear end of the medicine feeding channel. The invention realizes the automatic feeding of the bottled medicine and the special-shaped boxed medicine of the fast medicine dispensing machine, improves the medicine feeding efficiency, and the medicine feeding process is safe and reliable.

The invention discloses a subpackaging and sealing device for medical drugs. The subpackaging and sealing device comprises a placing base, wherein a sliding box is fixedly arranged on one side of the top of the placing base, a pulling assembly is movably arranged on one side of the sliding box in a sleeving mode, the other side of the pulling assembly is movably connected with a sliding connecting plate, the other side of the sliding connecting plate is movably connected with a sliding connecting base, the outer surface of the sliding connecting base is movably sleeved with a movable corner folding frame, the other end of the movable corner folding frame is movably sleeved with a special-shaped connecting assembly, and the bottom of the special-shaped connecting assembly is movably sleeved with a classified conveying assembly. According to the subpackaging and sealing device, the special-shaped connecting assembly, the classified conveying assembly and the like are arranged to cooperate with each other, convex arc structures on the surface of a tooth edge angle disc are used for limiting and blocking drug particles, so that the drug particles are prevented from being thrown out and falling off due to centrifugal force caused by too large rotating force, the subpackaging and sealing device is used for recycling, sealing and packaging of different particles, and the drugs are uniform and tidy.

The invention relates to a laboratory article, in particular to a combined medicinal spoon structure for taking drugs. The combined medicinal spoon comprises a spoon head and a handle detachably connected to the spoon head. The combined medicinal spoon is characterized in that: the spoon head comprises a square drug taking structure, a plug that is fixedly connected to the square drug taking structure to connect the handle, and a baffle plate plugged to the square drug taking structure. The combined medicinal spoon provided by the invention adopts a square head design and very thin edge, and also has an auxiliary baffle plate specially for blocking drugs so as to conveniently take redundant drugs out and taking drugs from a balance, and also the problems of error brought about by to-and-fro movement of weighing paper and sprinkling of drugs inside the balance can be avoided.

The present invention relates to a method for inducing a rapid eye movement sleep behavior disorder (RBD) phenotype that can be converted to a Parkinson's phenotype in a non-human test animal, the method comprising 1) unilateral treatment of the non-human test animal Or bilateral pontine tegmental dorsolateral inferior nucleus (SLD) stereotaxic injection of substances capable of inducing pathological changes in synuclein; 2) Assess the induction of RBD phenotype in the non-human test animals; 3) In the described Induction of Parkinsonian phenotypes was assessed in RBD animals. The invention also relates to a preparation method of a synuclein pathological RBD model. The present invention proposes to inject prefabricated fibrils (PFFs) that can induce synuclein pathology into SLD nuclei in a stereotaxic manner. It is expected that this model can provide an important animal model basis for elucidating the etiology, pathogenesis, and Parkinson's outcome of RBD in future research and developing effective blocking drugs.

The invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a medical application of EGCG monomer or compound, mainly for the preparation of EGCG monomer or the compound of EGCG and organic acid and / or sodium chloride in the treatment of esophageal cancer and the treatment of esophageal cancer. The use in the medicine of eating block sensation. The EGCG monomer or compound provided by the present invention can effectively treat or improve the patient’s sense of resistance to eating caused by esophageal squamous cell carcinoma, and the effective rate of treatment can reach more than 84%. The grade of esophageal pain decreased significantly, and the side effects were low.

The invention discloses an application of bone morphogenetic protein-4 in screening drugs for resisting cardiac hypertrophy, heart failure or cardiac fibrosis and belongs to the field of biomedicine. Screened drug types comprise: bone morphogenetic protein-4 formation inhibitor, bone morphogenetic protein-4 antagonistic, bone morphogenetic protein-4 receptor antagonists and bone morphogenetic protein-4 downstream signal antagonistic. The invention also relates to an application of the drugs in preparation of medicines for resisting cardiac hypertrophy, heart failure and arrhythmia. Researches have found that bone morphogenetic protein-4 can induce myocardial hypertrophy, apoptosis and cardiac fibroblast collagen secretion increase, lead to occurrence of cardiac hypertrophy, heart failure and arrhythmia. However, drugs for antagonism of bone morphogenetic protein-4 and its cell signaling pathway can be used to inhibit occurrence of cardiac hypertrophy, inhibit cardiac fibrosis and minimize occurrence of cardiac cell death and arrhythmia. The invention provides a theoretical basis for realizing high-flux medicine screening, and is of practical guiding significance.

The invention discloses new application of rapamycin in inhibiting propagation of plasmodium by entomoplily. The new application is characterized in that the rapamycin is used for decreasing the number of plasmodium oocysts in an entomoplily body; the rapamycin is used for improving the antiplasmodial infection ability of the entomoplily; and the rapamycin is used for improving the expression level of immune effector molecules TEP1 of the entomoplily. The invention also discloses application of the rapamycin in preparation of a reagent for inhibiting the propagation of the plasmodium by the entomoplily and a special preparation. It is discovered that the rapamycin can improve the ability of resisting mosquito infection by improving the expression level of PET-1, can achieve the purposes ofdecreasing the number of the plasmodium oocysts in the entomoplily body and effectively inhibiting the propagation of the plasmodium by anopheles, and the rapamycin can be used as a blocking drug ofthe propagation of the plasmodium by the mosquitoes.

The invention discloses a device used for nerve blocking drug injection and convenient to operate by a single person. The device comprises a base plate, a puncture needle, a pumpback unit and a drug injection unit, wherein a negative pressure indicating structure, a positive pressure indicating structure and a connector are arranged on the base plate; the negative pressure indicating structure andthe positive pressure indicating structure communicate with the connector through a pumpback pipeline and a drug injection pipeline respectively; press type switches are arranged on the pumpback pipeline and the drug injection pipeline; and the pumpback unit and the drug injection unit communicate with the negative pressure indicating structure and the positive pressure indicating structure respectively. By the adoption of the device for nerve blocking anesthesia drug injection, on one hand, the puncture needle, the pumpback unit and the drug injection unit are integrated through the base plate, so that single-person nerve blocking operation is achieved, the labor cost is saved, and meanwhile the accuracy and efficiency of anesthesia operation are improved; and on the other hand, a negative pressure state and a positive pressure state can be accurately displayed through the pressure indicating structures, so that the pain of a patient and the risk of anesthesia complications are reduced.